A Phase 4 interventional study of Pegloticase and Methotrexate (MTX) in Uncontrolled Gout and Chronic Gout, sponsored by Amgen. Completed at 12 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-19.
Sponsored by Amgen · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing pegloticase in Gout — 1 open to participants now, 1 under way, 1 of them phase 3. Pegloticase · Gout.
Among the 14 studies testing pegloticase in Gout, this one is the 8th largest by enrollment, is one of 2 that started in 2021, is one of 7 in phase 4, and was the 11th registered.
347 studies on the registry are indexed under Gout; 50 are open to participants now.
Browse Gout studies →1 of the 14 studies testing pegloticase in Gout is open now, in 2 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Puerto Rico
Ages 18+
By country, each count listing its studies:
Pegloticase: first FDA approval 2010 (KRYSTEXXA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is below the median of 83 across 288 interventional studies indexed under Gout.
Median enrollment 93 across the 14 interventional studies. Of the 13 that completed or were terminated, 11 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 14 have an industry lead sponsor. The 4 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 9 studies filed under Gout — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing pegloticase in Gout, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial is to assess efficacy, safety, blood levels and bodily effects of up to 2 dose levels of intravenous (IV) pegloticase (KRYSTEXXA) infusions at every 4 week intervals (Q4 Weeks) for up to 6 months (Day 1 to 24 weeks with an optional 24 - 48 weeks treatment duration) when given in combination with weekly oral doses of methotrexate (MTX). The goal is to identify an appropriate dose to be administered every 4 weeks to be used for future clinical trials for patients with chronic gout that does not adequately respond to conventional therapy.
The primary objective is to choose a dose for further investigation by assessing the effect of up to 2 dose levels of pegloticase administered IV Q4 weeks, co-administered with weekly doses of oral MTX, as measured by the sustained normalization of serum uric acid (sUA) to \< 6 mg/dL for at least 80% of the time during Month 6 and the duration of sUA to \< 6 mg/dL over 24 week treatment period in adult participants with chronic gout refractory to conventional therapy.
Acquired from Horizon in 2024.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Uncontrolled gout, defined as meeting the following criteria:
Symptoms of gout including at least 1 of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
16 mg IV dose of pegloticase q4 weeks with 15 mg methotrexate (MTX) weekly
Biological: Pegloticase · Drug: Methotrexate (MTX)
24 to 32 mg IV dose of pegloticase q4 weeks with 15 mg MTX weekly
Biological: Pegloticase · Drug: Methotrexate (MTX)
IV dose of pegloticase q4 weeks co-administered with weekly oral methotrexate
15 mg oral dose methotrexate administered weekly
Percentage of Participants Who Were Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6
Responders are defined as participants achieving and maintaining sUA \< 6 mg/dL for at least 80% of the time during Month 6. Participants meeting the sUA discontinuation criteria (pre-infusion sUA \>6 mg/dL at 2 consecutive scheduled trial visits beginning with the Week 1 Visit) were counted as non-responders.
Time frame: Month 6 (Weeks 20, 21, 22, 23, and 24)
Time to First sUA ≥6 mg/dL After First Achieving sUA <6 mg/dL, From the First Pegloticase Infusion Until Week 24
The number of participants who had pre-Infusion sUA ≥ 6 mg/dL post-day 1 pegloticase infusion were included in this analysis. The date of the first pre-infusion sUA ≥ 6 mg/dL was the event date. Participants who did not have the event were censored at the date of the last collected pre-infusion sample with non-missing sUA result. Participants who never achieved sUA \< 6 mg/dL were excluded from the analysis.
Time frame: Day 1 to Week 24
Maximum Concentration (Cmax) of Pegloticase
Noncompartmental Pharmacokinetic (PK) parameters of pegloticase were estimated using concentration data after the first dose (including Week 4 predose concentration data) using Phoenix WinNonlin® software. The linear/log trapezoidal rule was used in conjunction with the appropriate noncompartmental model, with input values for dose level, dosing time, serum concentration, and corresponding real-time values, based on drug dosing times whenever possible. Below limit of quantification (BLQ) values prior to the first quantifiable concentration were set to 0; BLQ values at all other time points were set to half the lower limit of quantification (LLOQ) (0.025 µg/mL).
Time frame: Post infusion on Day 1, at Weeks 1, 2, 3 and pre-dose at Week 4
Area Under the Concentration- Time Curve From Time 0 to Week 4 Predose of Pegloticase
Noncompartmental PK parameters of pegloticase were estimated using concentration data after the first dose (including Week 4 predose concentration data) using Phoenix WinNonlin® software. The linear/log trapezoidal rule was used in conjunction with the appropriate noncompartmental model, with input values for dose level, dosing time, serum concentration, and corresponding real-time values, based on drug dosing times whenever possible. BLQ values prior to the first quantifiable concentration were set to 0; BLQ values at all other time points were set to half LLOQ (0.025 µg/mL).
Time frame: Post infusion on Day 1, at Weeks 1, 2, 3 and pre-dose at Week 4
Trough Serum Concentration (Ctrough) of Pegloticase at Week 24 Pre-dose
Blood samples were collected for measurement of serum concentrations of pegloticase. The median concentration of pegloticase taken at Week 24 pre-dose was reported as the Ctrough concentration at Week 24.
Time frame: Week 24 Pre-dose
Percentage of Participants With Pre-infusion sUA <6 mg/dL at Each Scheduled Visit
The percentage of participants with pre-infusion sUA \<6 mg/dL at each scheduled infusion visit, regardless of treatment status, was presented.
Time frame: Pre-infusion on Day 1, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40 and 44
Area Under the sUA Concentration vs Time Curve From Day 1 to Week 24 and Day 1 to Week 48
The AUC from Day 1 to Week 24 and from Day 1 to Week 48 was calculated as time-adjusted AUC derived using the trapezoidal rule divided by the number of total days in the given period. The AUC from Day 1 to Week 48 was only calculated for participants who continued in the optional treatment period from Week 24 to Week 48.
Time frame: Day 1 to Week 24 and Day 1 to Week 48
Percentage of Time Participants Sustained sUA < 6 mg/dL From Day 1 to Week 24 or Day 1 to Week 48
The percentage of time that participants sustained sUA \< 6 mg/dL was derived using linear interpolation across all observed data points between Day 1 and the end of each analysis period. The percentage of time during a given period is the time that sUA \< 6 mg/dL divided by the total time from the first to the last scheduled visit in the given period.
Time frame: Day 1 to Week 24 and Day 1 to Week 48
Percentage of Participants With Anti-uricase Antibodies at Each Scheduled Visit
Pegloticase immunogenicity was assessed by incidence of anti-poly (Ethylene Glycol) (PEG) and anti-uricase immunoglobulin G (IgG) antibodies. The percentage of participants who were treatment-emergent anti-drug antibody (ADA) positive is presented below. Participants were considered treatment-emergent ADA positive if they were ADA negative at the data collection timepoint of Day 1 (Baseline) and ADA positive at one of the specified post-dose timepoints.
Time frame: Day 1 (Baseline) and Weeks 2, 4, 8, 16, 24, 36 and 48
Percentage of Participants With Anti-PEG Antibodies at Each Scheduled Visit
Pegloticase immunogenicity was assessed by incidence of anti-PEG and anti-uricase IgG antibodies. The percentage of participants who were treatment-emergent ADA positive is presented below. Participants were considered treatment-emergent ADA positive if they were ADA negative at the data collection timepoint of Day 1 (Baseline) and ADA positive at one of the specified post-dose timepoints.
Time frame: Day 1 (Baseline) and Weeks 2, 4, 8, 16, 24, 36 and 48
A total of 54 participants were enrolled into this trial in the United States between March 2021 and December 2023.
| Milestone | MTX Run-in | Pegloticase 16 mg + MTX | Pegloticase 30 mg + MTX |
|---|---|---|---|
| Started | 54 | 0 | 0 |
| Completed | 51 | 0 | 0 |
| Not completed | 3 | 0 | 0 |
| Withdrew: Screen failure | 3 | 0 | 0 |
| Milestone | MTX Run-in | Pegloticase 16 mg + MTX | Pegloticase 30 mg + MTX |
|---|---|---|---|
| Started | 0 | 25 | 26 |
| Completed | 0 | 22 | 24 |
| Not completed | 0 | 3 | 2 |
| Withdrew: Death | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 |
| Milestone | MTX Run-in | Pegloticase 16 mg + MTX | Pegloticase 30 mg + MTX |
|---|---|---|---|
| Started | 0 | 17 | 19 |
| Completed | 0 | 16 | 15 |
| Not completed | 0 | 1 | 4 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 4 |
Noncompartmental Pharmacokinetic (PK) parameters of pegloticase were estimated using concentration data after the first dose (including Week 4 predose concentration data) using Phoenix WinNonlin® software. The linear/log trapezoidal rule was used in conjunction with the appropriate noncompartmental model, with input values for dose level, dosing time, serum concentration, and corresponding real-time values, based on drug dosing times whenever possible. Below limit of quantification (BLQ) values prior to the first quantifiable concentration were set to 0; BLQ values at all other time points were set to half the lower limit of quantification (LLOQ) (0.025 µg/mL).
| μg/mL | Pegloticase 16 mg + MTX | Pegloticase 30 mg + MTX |
|---|---|---|
| Maximum Concentration (Cmax) of Pegloticase | 6.09 ± 33 | 11 ± 33 |
Noncompartmental PK parameters of pegloticase were estimated using concentration data after the first dose (including Week 4 predose concentration data) using Phoenix WinNonlin® software. The linear/log trapezoidal rule was used in conjunction with the appropriate noncompartmental model, with input values for dose level, dosing time, serum concentration, and corresponding real-time values, based on drug dosing times whenever possible. BLQ values prior to the first quantifiable concentration were set to 0; BLQ values at all other time points were set to half LLOQ (0.025 µg/mL).
| hr*μg/mL | Pegloticase 16 mg + MTX | Pegloticase 30 mg + MTX |
|---|---|---|
| Area Under the Concentration- Time Curve From Time 0 to Week 4 Predose of Pegloticase | 1670 ± 34 | 3120 ± 25 |
Blood samples were collected for measurement of serum concentrations of pegloticase. The median concentration of pegloticase taken at Week 24 pre-dose was reported as the Ctrough concentration at Week 24.
| μg/mL | Pegloticase 16 mg + MTX | Pegloticase 30 mg + MTX |
|---|---|---|
| Trough Serum Concentration (Ctrough) of Pegloticase at Week 24 Pre-dose | 1.33 (0.932 to 2.39) | 2.76 (2.10 to 3.11) |
The percentage of participants with pre-infusion sUA \<6 mg/dL at each scheduled infusion visit, regardless of treatment status, was presented.
| percentage of participants | Pegloticase 16 mg + MTX | Pegloticase 30 mg + MTX |
|---|---|---|
| Day 1 - Pre-infusion | 0 (0.0 to 13.7) | 3.8 (0.1 to 19.6) |
| Week 4 - Pre-infusion | 83.3 (62.6 to 95.3) | 84.6 (65.1 to 95.6) |
| Week 8 - Pre-infusion | 78.3 (56.3 to 92.5) | 84.6 (65.1 to 95.6) |
| Week 12 - Pre-infusion | 86.4 (65.1 to 97.1) | 87.5 (67.6 to 97.3) |
| Week 16 - Pre-infusion | 85.7 (63.7 to 97.0) | 83.3 (62.6 to 95.3) |
| Week 20 - Pre-infusion | 90.5 (69.6 to 98.8) | 82.6 (61.2 to 95.0) |
| Week 24 - Pre-infusion | 85.7 (63.7 to 97.0) | 82.6 (61.2 to 95.0) |
| Week 28 - Pre-infusion | 100 (80.5 to 100.0) | 88.9 (65.3 to 98.6) |
| Week 32 - Pre-infusion | 94.1 (71.3 to 99.9) | 88.9 (65.3 to 98.6) |
| Week 36 - Pre-infusion | 88.2 (63.6 to 98.5) | 88.2 (63.6 to 98.5) |
| Week 40 - Pre-infusion | 100 (78.2 to 100.0) | 88.2 (63.6 to 98.5) |
| Week 44 - Pre-infusion | 100 (79.4 to 100.0) | 86.7 (59.5 to 98.3) |
The AUC from Day 1 to Week 24 and from Day 1 to Week 48 was calculated as time-adjusted AUC derived using the trapezoidal rule divided by the number of total days in the given period. The AUC from Day 1 to Week 48 was only calculated for participants who continued in the optional treatment period from Week 24 to Week 48.
| mg/dL | Pegloticase 16 mg + MTX | Pegloticase 30 mg + MTX |
|---|---|---|
| Day 1 to Week 24 | 1.4 ± 2.47 | 1.3 ± 2.24 |
| Day 1 to Week 48 | 0.3 ± 0.78 | 0.8 ± 2.24 |
The percentage of time that participants sustained sUA \< 6 mg/dL was derived using linear interpolation across all observed data points between Day 1 and the end of each analysis period. The percentage of time during a given period is the time that sUA \< 6 mg/dL divided by the total time from the first to the last scheduled visit in the given period.
| percentage of time | Pegloticase 16 mg + MTX | Pegloticase 30 mg + MTX |
|---|---|---|
| Day 1 to Week 24 | 87.3 ± 25.55 | 87.9 ± 22.76 |
| Day 1 to Week 48 | 98.5 ± 4.03 | 91.4 ± 25.57 |
Pegloticase immunogenicity was assessed by incidence of anti-poly (Ethylene Glycol) (PEG) and anti-uricase immunoglobulin G (IgG) antibodies. The percentage of participants who were treatment-emergent anti-drug antibody (ADA) positive is presented below. Participants were considered treatment-emergent ADA positive if they were ADA negative at the data collection timepoint of Day 1 (Baseline) and ADA positive at one of the specified post-dose timepoints.
| percentage of participants | Pegloticase 16 mg + MTX | Pegloticase 30 mg + MTX |
|---|---|---|
| Treatment-Emergent ADA Positive at Week 2 | 0 | 0 |
| Treatment-Emergent ADA Positive at Week 4 | 0 | 0 |
| Treatment-Emergent ADA Positive at Week 8 | 0 | 0 |
| Treatment-Emergent ADA Positive at Week 16 | 23.8 | 4.3 |
| Treatment-Emergent ADA Positive at Week 24 | 18.2 | 8.3 |
| Treatment-Emergent ADA Positive at Week 36 | 0 | 16.7 |
| Treatment-Emergent ADA Positive at Week 48 | 6.7 | 6.7 |
Pegloticase immunogenicity was assessed by incidence of anti-PEG and anti-uricase IgG antibodies. The percentage of participants who were treatment-emergent ADA positive is presented below. Participants were considered treatment-emergent ADA positive if they were ADA negative at the data collection timepoint of Day 1 (Baseline) and ADA positive at one of the specified post-dose timepoints.
| percentage of participants | Pegloticase 16 mg + MTX | Pegloticase 30 mg + MTX |
|---|---|---|
| Treatment-Emergent ADA Positive at Week 2 | 13.0 | 12.0 |
| Treatment-Emergent ADA Positive at Week 4 | 24.0 | 15.4 |
| Treatment-Emergent ADA Positive at Week 8 | 25.0 | 42.3 |
| Treatment-Emergent ADA Positive at Week 16 | 14.3 | 26.1 |
| Treatment-Emergent ADA Positive at Week 24 | 22.7 | 25.0 |
| Treatment-Emergent ADA Positive at Week 36 | 17.6 | 22.2 |
| Treatment-Emergent ADA Positive at Week 48 | 6.7 | 13.3 |
Responders are defined as participants achieving and maintaining sUA \< 6 mg/dL for at least 80% of the time during Month 6. Participants meeting the sUA discontinuation criteria (pre-infusion sUA \>6 mg/dL at 2 consecutive scheduled trial visits beginning with the Week 1 Visit) were counted as non-responders.
| percentage of participants | Pegloticase 16 mg + MTX | Pegloticase 30 mg + MTX |
|---|---|---|
| Percentage of Participants Who Were Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6 | 68.0 (46.5 to 85.1) | 73.1 (52.2 to 88.4) |
The number of participants who had pre-Infusion sUA ≥ 6 mg/dL post-day 1 pegloticase infusion were included in this analysis. The date of the first pre-infusion sUA ≥ 6 mg/dL was the event date. Participants who did not have the event were censored at the date of the last collected pre-infusion sample with non-missing sUA result. Participants who never achieved sUA \< 6 mg/dL were excluded from the analysis.
| days | Pegloticase 16 mg + MTX | Pegloticase 30 mg + MTX |
|---|---|---|
| Time to First sUA ≥6 mg/dL After First Achieving sUA <6 mg/dL, From the First Pegloticase Infusion Until Week 24 | 51.5 ± 39.49 | 45.1 ± 37.19 |
Collected over MTX run-in period: Week -4 to Day 1; pegloticase + MTX treatment period: Day 1 to Week 48. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MTX Run-in | 0/54 (0%) | 0/54 (0%) | 21/54 (38.9%) |
| Pegloticase 16 mg + MTX | 1/25 (4%) | 3/25 (12%) | 19/25 (76%) |
| Pegloticase + 30 mg MTX | 0/26 (0%) | 0/26 (0%) | 21/26 (80.8%) |
| Event | MTX Run-in | Pegloticase 16 mg + MTX | Pegloticase + 30 mg MTX |
|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/54 | 1/25 | 0/26 |
| Anaphylactic reactionImmune system disorders | 0/54 | 1/25 | 0/26 |
| COVID-19Infections and infestations | 0/54 | 1/25 | 0/26 |
| Transient ischaemic attackNervous system disorders | 0/54 | 1/25 | 0/26 |
| Event | MTX Run-in | Pegloticase 16 mg + MTX | Pegloticase + 30 mg MTX |
|---|---|---|---|
| GoutMetabolism and nutrition disorders | 17/54 | 18/25 | 20/26 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/54 | 3/25 | 3/26 |
| Muscle strainInjury, poisoning and procedural complications | 0/54 | 0/25 | 3/26 |
| NauseaGastrointestinal disorders | 2/54 | 2/25 | 0/26 |
| VomitingGastrointestinal disorders | 0/54 | 2/25 | 0/26 |
| COVID-19Infections and infestations | 0/54 | 2/25 | 2/26 |
| Glomerular filtration rate decreasedInvestigations | 1/54 | 2/25 | 0/26 |
| White blood cell count decreasedInvestigations | 2/54 | 2/25 | 0/26 |
| DizzinessNervous system disorders | 0/54 | 2/25 | 0/26 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/54 | 2/25 | 1/26 |
Safety analysis set: All enrolled participants who received at least 1 dose of pegloticase + MTX during the trial.
| Age, Continuous(years) | Pegloticase 16 mg + MTX | Pegloticase 30 mg + MTX | Total |
|---|---|---|---|
| Mean | 54.2 ± 9.56 | 55.8 ± 8.74 | 55.0 ± 9.09 |
| Sex: Female, Male(Participants) | Pegloticase 16 mg + MTX | Pegloticase 30 mg + MTX | Total |
|---|---|---|---|
| Female | 2 | 1 | 3 |
| Male | 23 | 25 | 48 |
| Ethnicity (NIH/OMB)(Participants) | Pegloticase 16 mg + MTX | Pegloticase 30 mg + MTX | Total |
|---|---|---|---|
| Hispanic or Latino | 16 | 10 | 26 |
| Not Hispanic or Latino | 9 | 16 | 25 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Pegloticase 16 mg + MTX | Pegloticase 30 mg + MTX | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 2 | 5 |
| White | 21 | 24 | 45 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jan 2021 to primary completion in May 2023, 27 months.
Results were first posted in May 2026, 3 years after primary completion. A results delay was requested in May 2024.
Of 19 phase 4 interventional studies under Gout, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 27 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pegloticase · Methotrexate